FDA's Sarepta ruling injects a shot of reality into the biotech world

11/14/2013 | Forbes

The FDA recently told Sarepta Therapeutics not to file for fast-track approval of eteplirsen, a drug candidate for Duchenne muscular dystrophy, sending the company's share prices down and dashing the hopes of children with the debilitating disease and their parents. The decision presents a warning for biotechnology investors, Matthew Herper writes. "One of the key ideas that has driven biotechnology stocks into a frothy bubble is the perception that the FDA has become friendlier to companies than it was before. Either that is no longer true or it never really was," he writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care